Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSAZ Non-Formulary Drug Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of ArizonaPolicy P096.4

    Non-Formulary Medications Coverage Guideline (for Closed Formularies)

    Customize your policy alerts

    Sign up for blue cross blue shield - arizona Policy P096.4 alerts

    Get alerted when Policy P096.4 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Pharmacy Coverage Guideline establishes medical necessity and prior authorization requirements for non-formulary medications without a specific BCBSAZ drug coverage guideline or drug-specific step-therapy criteria. It applies to Commercial and Marketplace plans and excludes Federal Employee Program, Medicare Advantage, Medicaid, and out-of-state Blue Cross and/or Blue Shield plans.

    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyNon-Formulary Medications Coverage Guideline (for Closed Formularies)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 16, 2024
    Next Review DateN/A
    Key ActionSubmit a fully completed and signed prior authorization request with chart notes, laboratory results, and supporting clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Commercial + MarketplaceApplicable plans
    3+Formulary alternatives required
    3 months eachGeneric trial duration
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial approval
    12 monthsContinuation approval
    4Excluded plan types

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when all applicable requirements are met.

    Initial therapy requirements

    • Prescriber and indication: The medication is prescribed by a physician specializing in the diagnosis or in consultation with a physician in the clinically appropriate specialty, and the diagnosis is consistent with FDA-approved product labeling.
    • Age and baseline evaluation: The patient age, required baseline tests, requested dosage, and duration of use are consistent with FDA-approved product labeling.
    • Alternative formulary therapy: The member has failed, is contraindicated for, or is intolerant to three or more formulary medications approved by the FDA for the indication or diagnosis, if available.Three or more medications

      Failure, contraindication, or intolerance may satisfy the alternative-therapy requirement.

    • Safety and benefit conditions: The product has established safety and efficacy for the condition or diagnosis; no FDA label contraindication or other significant exclusion to use applies; no significant interacting drug is present; and the individual does not have a conflicting benefit exclusion.
    • Documentation: A completed request form, including chart notes, lab results, and supporting clinical documentation, is submitted.

    Continuation Therapy

    Continuation or renewal therapy requires all applicable criteria below.

    Continuation therapy requirements

    • Prescriber qualification: The member continues to be seen by a physician specializing in the condition or is in consultation with a physician in the clinically appropriate specialty.
    • Clinical response and continued need

      • Positive clinical response: There is no evidence of disease progression, no significant unacceptable adverse drug reactions, documented evidence of efficacy, disease stability and/or improvement, and the member has achieved and maintains most activities of daily living.
    • Adherence to the prescribed therapy regimen has been documented.
    • Brand-specific requirement when applicable:

    This guideline applies to Commercial and Marketplace plans. It does not apply to the Federal Employee Program, Medicare Advantage, Medicaid, or members of out-of-state Blue Cross and/or Blue Shield plans.

    Coverage is excluded when an FDA label contraindication, another significant exclusion to use, or a significant interacting drug is present.

    Coverage is excluded when the individual has a conflicting benefit exclusion.

    Coverage is excluded when an FDA label contraindication or other significant exclusion is present, or when a significant interacting drug is identified.

    Coverage is excluded when the individual has a conflicting benefit exclusion.

    Prior Authorization and Provider Requirements

    Prior Authorization

    Complete Prior Authorization Request

    Submit a complete prior authorization request for the medication-specific review. Use the applicable request form and include all required clinical and supporting information.

    • Complete and sign the medication-specific prior authorization request form.
    • Include chart notes, laboratory results, and other supporting clinical documentation.
    Prior Authorization

    Non-Formulary Authorization Request

    For a non-formulary medication, submit a request that identifies the medication and regimen and explains the condition being treated. Include the clinical details and supporting results needed for review.

    • Medication name, dose, frequency, and anticipated length of therapy.
    • Disease or condition being treated, including severity.
    • Previously tried agents and information about failure, ineffective treatment, adverse drug events, contraindications, or non-adherence.

    Guideline Background

    This guideline addresses non-formulary medications that do not have a specific BCBSAZ drug coverage guideline or drug-specific step-therapy criteria. Coverage decisions consider FDA-approved labeling, clinical safety and efficacy, required baseline evaluation, prior treatment history, and the member’s benefit provisions.

    Definitions

    FDA
    TermFDA
    Full nameFood and Drug Administration
    Reference nameU.S. Food and Drug Administration (FDA)
    Medication Product Labeling
    TermMedication Product Labeling
    DefinitionManufacturer FDA approved product information
    Information sourceManufacturer product information approved by the Food and Drug Administration

    Initial Therapy Criteria

    Initial Non-Formulary Medication Therapy

    Initial therapy may be covered when all applicable requirements are met.

    Initial non-formulary medication coverage

    • Prescriber and FDA labeling: The prescriber is appropriately qualified, and the diagnosis, patient age, requested dosage, duration of use, and all required baseline tests are consistent with FDA-approved product labeling.
    • Alternative formulary therapy: The member has failed, is contraindicated for, or is intolerant to three or more formulary medications approved by the FDA for the indication or diagnosis, if available.Three or more formulary medications when available
    • Safety and benefit conditions: The product has established safety and efficacy for the condition or diagnosis; no FDA label contraindication or other significant exclusion to use applies; no significant interacting drug is present; and the individual does not have a conflicting benefit exclusion.

    Continuation and Renewal Criteria

    Renewal Therapy

    Continuation or renewal therapy requires all applicable criteria below.

    Renewal therapy requirements

    • Specialty care: The member remains under the care of a physician specializing in the condition or in consultation with a clinically appropriate specialty.
    • Benefit from therapy and continued need

      • Positive clinical response: There is no evidence of disease progression, no significant unacceptable adverse drug reactions, documented evidence of efficacy, disease stability and/or improvement, and the member has achieved and maintains most activities of daily living.
    • Adherence to the prescribed therapy regimen has been documented.

    Step-Therapy Requirements

    StepRequired trialOutcome requirement
    1Three or more FDA-approved formulary medications for the indication or diagnosis, if availableFailure, contraindication, or intolerance
    StepRequired trialOutcome requirementMinimum duration
    1Three available generic equivalents for a brand-specific request, if availableFailure, contraindication, or intoleranceAt least three months for each generic equivalent
    StepRequirementMinimum durationAdditional instruction
    1Brand-specific requests require failure, contraindication, or intolerance with three available generic equivalents, if availableAt least three months for each generic equivalentReport any failure, contraindication, or intolerance to the FDA
    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyNon-Formulary Medications Coverage Guideline (for Closed Formularies)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 16, 2024
    Next Review DateN/A
    Key ActionSubmit a fully completed and signed prior authorization request with chart notes, laboratory results, and supporting clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider RequirementsGuideline BackgroundDefinitionsInitial Therapy CriteriaContinuation and Renewal CriteriaStep-Therapy Requirements
    For a brand-specific request, the member has failed, is contraindicated for, or is intolerant to three generic equivalents, if available, for at least three months each.
    Three generic equivalents; at least three months each

    Any failure, contraindication, or intolerance to the generic drugs should be reported to the Food and Drug Administration.

  1. Safety: No FDA label contraindication or other significant exclusion applies, and no significant interacting drug is present.
  2. Benefit eligibility: The individual does not have a conflicting benefit exclusion.
  3. Documentation: Chart notes, supporting clinical documentation with evidence of improvement in the given indication, and laboratory values confirming safe use are submitted.
  4. Applicable laboratory and other test results, plus additional supporting literature or clinical guidelines when available.
  5. Step Therapy

    Document Three Formulary Alternatives

    When available, document failure, contraindication, or intolerance to three or more FDA-approved formulary medications for the requested indication or diagnosis.

    • Identify each formulary alternative and the relevant failure, contraindication, or intolerance.
    • Do not use patient samples as evidence of an adequate initial trial or failure.
    Step Therapy

    Trial Generic Equivalents for Brand Requests

    For a brand-specific request, document trials of three available generic equivalents for at least three months each, when available.

    • Record the generic product, trial duration, outcome, and reason for failure, contraindication, or intolerance.
    • Report failure, contraindication, or intolerance to generic drugs to the Food and Drug Administration as directed in the guideline.
    Denial Risk

    Generic-Equivalent Requirement

    Brand-specific requests require documented failure, contraindication, or intolerance with three available generic equivalents, when available.

    • Each generic-equivalent trial must be at least three months.
    • Explain the clinical basis for each failure, contraindication, or intolerance.
    Documentation Required

    Provide Required Clinical Documentation

    Provide the completed request form and the clinical records needed to establish medical necessity and safe use.

    • Completed request form.
    • Chart notes.
    • Laboratory results.
    • Supporting clinical documentation.
    Prior Authorization

    Sign and Submit the Request

    The prescribing provider must sign the completed request form and submit it through BCBSAZ Pharmacy Management.

    • Fax: (602) 864-3126.
    • Email: Pharmacyprecert@azblue.com.
    • Medication prior authorization information and forms are available at www.azblue.com/pharmacy.
    Documentation Required

    Support Continuation of Therapy

    For continuation or renewal requests, provide current documentation showing that treatment remains clinically appropriate and safe.

    • Chart notes with evidence of improvement for the treated indication.
    • Supporting clinical documentation.
    • Laboratory values that confirm safe use.
    Documentation Required

    Include Complete Request Information

    Include all information necessary to evaluate the non-formulary medication request and its anticipated use.

    • Medication name.
    • Dose and frequency.
    • Anticipated treatment duration.
    • Disease or condition being treated and its severity.
    • Previously tried agents and outcomes, including failure, ineffectiveness, adverse drug events, contraindications, or non-adherence.
    • Applicable laboratory and other test results.
    Denial Risk

    Meet FDA-Label and Safety Requirements

    Requests may be denied when the diagnosis, patient age, dosage, duration, or baseline evaluation is inconsistent with FDA-approved product labeling.

    • Diagnosis must be consistent with the FDA-approved indication.
    • Age must be consistent with FDA-approved labeling.
    • Complete all baseline tests required by the FDA-approved labeling before treatment.
    • Requested dosage and duration must be consistent with FDA-approved labeling.
    • The product must have established safety and efficacy for the condition or diagnosis.
    • No FDA-label contraindications, significant exclusions, or significant interacting drugs may apply.
    • A conflicting benefit exclusion must not apply.
    Denial Risk

    Document Required Medication Trials

    Requests may be denied when the required formulary alternatives or generic-equivalent trials are not documented.

    • Document failure, contraindication, or intolerance to three or more FDA-approved formulary medications when available.
    • For brand-specific requests, document failure, contraindication, or intolerance to three available generic equivalents for at least three months each, when available.
    Denial Risk

    Avoid an Incomplete Submission

    An incomplete prior authorization submission may delay processing or result in denial. Submit the completed form with the provider signature and all required clinical records.

    • Completed request form.
    • Prescriber signature.
    • Chart notes.
    • Laboratory results.
    • Supporting clinical documentation.
    • Submit by fax or email using the BCBSAZ Pharmacy Management instructions.
    Denial Risk

    Check Safety Exclusions

    Coverage may be denied when FDA-label contraindications, significant exclusions, or significant interacting drugs make the requested medication unsafe.

    • Review FDA-label contraindications and other significant exclusions.
    • Assess for significant interacting drugs before submission.
    Denial Risk

    Check for Benefit Exclusions

    Coverage may be denied when a conflicting benefit exclusion applies to the individual or requested medication.

    • Verify that no conflicting benefit exclusion applies before submitting the request.
    Note

    Route Off-Label Requests

    Route requests for non-FDA-approved uses or for dosing, frequency, or duration outside FDA-approved parameters to the applicable off-label Pharmacy Coverage Guideline.

    • Off-Label Use of Non-Cancer Medications.
    • Off-Label Use of Cancer Medications.
  6. Authorization documentation: A completed request form, including chart notes, lab results, and supporting clinical documentation, is submitted.
  7. Initial Therapy

    Initial therapy requests are subject to the non-formulary medication requirements and approval duration.

    Initial request information

    • FDA-approved medication: The requested medication is FDA approved.FDA-approved medication
    • Required request details: The request identifies the medication name, dose, frequency, anticipated length of therapy, disease or condition being treated and its severity, previously tried agents and treatment outcomes, and all applicable laboratory and other test results.
    • Approval duration: If approved, initial therapy authorization is for six months or until the end of the plan year, whichever applies.6 months or end of plan year
    Brand-specific requirement when applicable: For a brand-specific request, the member has failed, is contraindicated for, or is intolerant to three generic equivalents, if available, for at least three months each.Three generic equivalents; at least three months each

    Any failure, contraindication, or intolerance to the generic drugs should be reported to the Food and Drug Administration.

  8. Safety and benefit conditions: No FDA label contraindication or other significant exclusion applies, no significant interacting drug is present, and the individual does not have a conflicting benefit exclusion.
  9. Continuation documentation: Chart notes, supporting clinical documentation with evidence of improvement in the given indication, and laboratory values confirming safe use are submitted.